# Outpatient Treatment With Anti-Coronavirus Immunoglobulin

> **NCT04910269** · PHASE3 · RECRUITING · sponsor: **University of Minnesota** · enrollment: 820 (estimated)

## Conditions studied

- COVID
- SARS-CoV2 Infection
- Covid19

## Interventions

- **BIOLOGICAL:** Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04910269
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-06
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 820 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04910269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04910269, "Outpatient Treatment With Anti-Coronavirus Immunoglobulin". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04910269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*